These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31870626)

  • 1. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa.
    Ghias MH; Hyde MJ; Tomalin LE; Morgan BP; Alavi A; Lowes MA; Piguet V
    J Invest Dermatol; 2020 Mar; 140(3):531-536.e1. PubMed ID: 31870626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa.
    Grand D; Navrazhina K; Frew JW
    Exp Dermatol; 2020 Jan; 29(1):86-92. PubMed ID: 31688984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26.
    Scala E; Di Caprio R; Cacciapuoti S; Caiazzo G; Fusco A; Tortorella E; Fabbrocini G; Balato A
    Br J Dermatol; 2019 Nov; 181(5):1038-1045. PubMed ID: 30829398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement inhibitors are not useful in secondary hemolytic uremic syndromes.
    Duineveld C; Wetzels JFM
    Kidney Int; 2019 Oct; 96(4):829-833. PubMed ID: 31543154
    [No Abstract]   [Full Text] [Related]  

  • 5. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model.
    Vossen ARJV; van der Zee HH; Prens EP
    Front Immunol; 2018; 9():2965. PubMed ID: 30619323
    [No Abstract]   [Full Text] [Related]  

  • 6. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?
    Kanni T; Zenker O; Habel M; Riedemann N; Giamarellos-Bourboulis EJ
    Br J Dermatol; 2018 Aug; 179(2):413-419. PubMed ID: 29405257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement in skin diseases.
    Kotnik V
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):3-11. PubMed ID: 21879199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement Activation in Inflammatory Skin Diseases.
    Giang J; Seelen MAJ; van Doorn MBA; Rissmann R; Prens EP; Damman J
    Front Immunol; 2018; 9():639. PubMed ID: 29713318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normal Skin Microbiota is Altered in Pre-clinical Hidradenitis Suppurativa.
    Ring HC; Bay L; Kallenbach K; Miller IM; Prens E; Saunte DM; Bjarnsholt T; Jemec GB
    Acta Derm Venereol; 2017 Feb; 97(2):208-213. PubMed ID: 27377144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa.
    Prens LM; Ardon CB; van Straalen KR; van der Zee HH; Seelen MAJ; Laman JD; Prens EP; Horváth B; Damman J
    J Invest Dermatol; 2021 Dec; 141(12):2966-2969.e1. PubMed ID: 34252397
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4.
    Penno CA; Jäger P; Laguerre C; Hasler F; Hofmann A; Gass SK; Wettstein-Ling B; Schaefer DJ; Avrameas A; Raulf F; Wieczorek G; Lehmann JCU; Loesche C; Roth L; Röhn TA
    J Invest Dermatol; 2020 Dec; 140(12):2421-2432.e10. PubMed ID: 32387270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yin and Yang: A disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa.
    Schell SL; Schneider AM; Nelson AM
    Exp Dermatol; 2021 Oct; 30(10):1453-1470. PubMed ID: 34018644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction?
    Johnston DGW; Kirby B; Tobin DJ
    Exp Dermatol; 2021 Oct; 30(10):1554-1568. PubMed ID: 34418166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa.
    Schneider AM; Cook LC; Zhan X; Banerjee K; Cong Z; Imamura-Kawasawa Y; Gettle SL; Longenecker AL; Kirby JS; Nelson AM
    J Invest Dermatol; 2020 Mar; 140(3):716-720. PubMed ID: 31465743
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathogenesis and pharmacotherapy of Hidradenitis suppurativa.
    Nazary M; van der Zee HH; Prens EP; Folkerts G; Boer J
    Eur J Pharmacol; 2011 Dec; 672(1-3):1-8. PubMed ID: 21930119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa.
    Guenin-Macé L; Morel JD; Doisne JM; Schiavo A; Boulet L; Mayau V; Goncalves P; Duchatelet S; Hovnanian A; Bondet V; Duffy D; Ungeheuer MN; Delage M; Nassif A; Di Santo JP; Demangel C
    JCI Insight; 2020 Oct; 5(20):. PubMed ID: 32970636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.
    Del Duca E; Morelli P; Bennardo L; Di Raimondo C; Nisticò SP
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on pathogenesis of hidradenitis suppurativa.
    Napolitano M; Fabbrocini G; Marasca C; Monfrecola G
    G Ital Dermatol Venereol; 2018 Jun; 153(3 Suppl 2):3-7. PubMed ID: 30468374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidradenitis suppurativa: the role of immune dysregulation.
    Kelly G; Sweeney CM; Tobin AM; Kirby B
    Int J Dermatol; 2014 Oct; 53(10):1186-96. PubMed ID: 24961484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microbiome in Hidradenitis Suppurativa-What We Know and Where We Are Heading.
    Świerczewska Z; Lewandowski M; Surowiecka A; Barańska-Rybak W
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.